Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAmanda Morgan - Chief Commercial OfficerAnthony Petrone - Managing Director of Equity ResearchKarishma Raghuram - Biotechnology Equity Research AssociateLarry Solow - Managing DirectorMark Kinarney - VP of Investor RelationsMary Anne Heino - Executive Chairperson and Interim CEORobert Marshall - CFO and TreasurerYuan Zhi - Managing DirectorConference Call ParticipantsAndy Hsieh - Biotechnology AnalystJustin Wals ...

Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAmanda Morgan - Chief Commercial OfficerAnthony Petrone - Managing Director of Equity ResearchKarishma Raghuram - Biotechnology Equity Research AssociateLarry Solow - Managing DirectorMark Kinarney - VP of Investor RelationsMary Anne Heino - Executive Chairperson and Interim CEORobert Marshall - CFO and TreasurerYuan Zhi - Managing DirectorConference Call ParticipantsAndy Hsieh - Biotechnology AnalystJustin Wals ...

Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker10Good morning. Welcome to Lantheus' fourth quarter and full year 2025 conference call. All lines have been placed on mute. This call is being recorded. A replay will be available in the Investors section of the company's website approximately two hours after the completion of the call, and will be archived for at least 30 days. I'll now turn the call over to Mark Guarnieri, Vice President of Investor Relations. Mark?Speaker ...

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpen ...

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthcare Conferenc ...

Core Viewpoint - Perspective Therapeutics, Inc. has announced an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $175 million to support its clinical development and operational needs [1][3]. Group 1: Offering Details - The company is offering 39,576,088 shares of common stock at $3.79 per share and pre-funded warrants for 6,598,046 shares at $3.789 each, with gross proceeds expected to be around $175 million before expenses [1]. - The offering is set to close on or about February 3, 2026, pending customary closing conditions [1]. Group 2: Investor Participation - Notable investors in the financing include Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital, Affinity Asset Advisors, HBM Healthcare Investments, and Ally Bridge Group [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical development, investing in manufacturing facilities, and general corporate purposes, with potential for acquiring complementary products or technologies [3]. Group 4: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that targets cancer cells with alpha-emitting isotopes [7]. - The company is also working on complementary imaging diagnostics to enhance treatment personalization and efficacy [7]. - Current clinical programs include neuroendocrine tumors, melanoma, and solid tumors, which are in Phase 1/2a trials in the U.S. [8].

Core Insights - Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, meeting its upgraded guidance of $800-$820 million [1] - The company experienced a significant 46% year-over-year increase in fourth quarter revenue, totaling around $208 million [2] - The Precision Medicine business generated approximately $161 million in revenue, reflecting a 4% quarter-over-quarter growth driven by the successful U.S. launch of Gozellix [2] Financial Performance - Fiscal 2025 revenue was approximately $804 million, aligning with guidance [1] - Fourth quarter revenue increased by 46% year-over-year to around $208 million [2] - Precision Medicine revenue was approximately $161 million, with a 4% quarter-over-quarter growth [2] Clinical Advancements - The company is advancing clinical studies, including the ProstACT Global Phase 3 study and the SOLACE Phase 1 study in the U.S. [3] - Telix dosed the first patient in the U.S. for the BiPASS Phase 3 trial to evaluate its PSMA-PET imaging agents [4] Strategic Collaborations - Telix announced a strategic collaboration with Varian to explore the combination of its radiopharmaceuticals with external beam radiation therapy [5] Stock Performance - Telix stock is currently trading 5.5% below its 20-day simple moving average and 22.6% below its 100-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by 56.91% [6] - The stock carries a Buy Rating with an average price target of $21.20, despite trading at a premium P/E multiple [8] Analyst Insights - Analysts view the shift from a diagnostic-focused business to a pure-play radiopharmaceutical company as a positive development [9] - The bull case for Telix is based on the potential for durable cash flows from Illuccix and Gozellix [9] Market Position - Telix Pharmaceuticals' Benzinga Edge scorecard indicates a challenging outlook, with low momentum and a premium value score [10] - The stock was down 6.86% at $7.20 at the time of publication [11]

Summary of Radiopharm Theranostics Conference Call Company Overview - **Company Name**: Radiopharm Theranostics - **Stock Symbols**: NASDAQ: RADX, ASX: RAD - **Industry**: Clinical stage radiotherapeutics - **Focus**: Development of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical needs [2][3] Core Business and Partnerships - **Core Business**: Radiopharmaceuticals, with a focus on first-in-class products [3] - **Strategic Partnerships**: - **Lantheus**: Largest shareholder with approximately 15% ownership [3] - **MD Anderson Cancer Center**: Scientific partnership for research and development [3] Pipeline and Clinical Trials - **Clinical Stage Molecules**: Five molecules currently in clinical stage [3] - **Key Products**: - **RAD101**: Imaging agent for brain metastasis, currently in Phase II with over 50% trial recruitment [4][6] - **PD-L1 Nanobody**: In Phase I, targeting multiple solid tumors [10] - **HER2 Nanobody**: In Phase I, targeting breast and gastroesophageal cancer [10] - **RV01**: Monoclonal antibody targeting B7-H3, expected to dose first patient in February [5] - **KLK3-targeting Monoclonal Antibody**: Radiolabeled with Terbium-161, also expected to dose first patient soon [5] Clinical Milestones and Data - **Upcoming Milestones**: - Completion of Phase II enrollment for RAD101 expected by March or April 2026 [14] - Full data release for Phase II anticipated before June 2026 [14] - Significant clinical data for RAD204 and RAD102 expected mid-2026 [14] - **Interim Data**: Positive interim results for RAD101, with 92% of patients achieving primary endpoint [7][8] Market Position and Competition - **Competitive Advantage**: No other radiopharmaceuticals in development for brain metastasis imaging, positioning RAD101 as a first-in-class product [16] - **Comparison with Competitors**: - **Novartis**: Established leader with commercial products but focused on different therapeutic areas [24] - **Telix**: More focused on imaging rather than therapeutics [24] - **Point Biopharma**: Acquired by Lilly, with no direct competition to Radiopharm's pipeline [25] Financial Overview - **Burn Rate**: Approximately $6 million to $7 million per quarter, with sufficient cash to reach Q1 2027 [19] - **Revenue Generation Potential**: RAD101 is closest to commercialization, with potential market launch by 2029 [21] Supply Chain and Manufacturing - **Isotope Supply Chain**: Multiple suppliers secured for Lutetium-177 to ensure reliable supply [18] Strategic Vision - **Partnership Strategy**: Focus on clinical development with openness to partnerships or licensing as trials progress [27] - **Long-term Goals**: Aim to deliver clinical data in 2026 that supports future financing needs [19][29] Conclusion - **Outlook**: 2026 is expected to be a pivotal year for Radiopharm Theranostics, with a strong focus on execution and addressing unmet medical needs in cancer treatment [29]

Core Viewpoint - Lantheus Holdings, Inc. has completed the sale of its SPECT business to SHINE Technologies, allowing the company to focus on its growing portfolio of PET radiodiagnostics and microbubbles while advancing its pipeline of radiopharmaceuticals [1][2]. Company Overview - Lantheus is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [29]. - The company has been providing radiopharmaceutical solutions for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [29]. Transaction Details - The sale includes Lantheus' SPECT business, diagnostic agents such as TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite, as well as the manufacturing facility in North Billerica, Massachusetts, and related Canadian operations [1]. - Solomon Partners Securities, LLC acted as the financial advisor for Lantheus during this transaction, with Foley Hoag LLP and Ropes & Gray LLP serving as legal advisors, and Ernst & Young LLP providing financial and tax advisory services [3]. SHINE Technologies Overview - SHINE Technologies, LLC is an industry leader in next-generation fusion technology, focusing on safety, cost-efficiency, and environmental responsibility [30]. - The company has successfully commercialized fusion technology across various applications, including medical isotope production essential for diagnosing heart disease and cancer [31]. - SHINE is also pioneering nuclear waste recycling to enhance the sustainability of nuclear energy and aims to change energy production through commercializing fusion energy [32].

Core Insights - Nitorum Capital has fully exited its stake in Lantheus Holdings, selling 344,444 shares for approximately $28.2 million, indicating potential concerns regarding the company's investment case due to shrinking margins and leadership changes [1][2]. Company Overview - Lantheus Holdings is a prominent developer and manufacturer of imaging diagnostics and targeted therapeutics for oncology and cardiology, with a strong presence in the radiopharmaceuticals market [6]. - The company reported a total revenue of $1.53 billion and a net income of $167.68 million for the trailing twelve months (TTM) [4]. Financial Performance - Lantheus generated $384 million in revenue for the third quarter, with nearly $95 million in free cash flow, although the quality of earnings is under pressure as GAAP EPS fell to $0.41 from $1.79 year-over-year [9]. - The company's flagship product, iPYLARIFY, experienced a 7.4% decline in sales year-over-year, despite growth in precision diagnostics revenue elsewhere [10]. Market Position - As of June 30, Lantheus represented 4.2% of Nitorum Capital's assets under management (AUM), which now totals $569.28 million across 27 positions following the sale [2][3]. - Lantheus shares are currently priced at $66.53, reflecting a 27% decline over the past year, significantly underperforming the S&P 500, which has increased by 15% during the same period [3]. Strategic Challenges - The company is facing challenges including a CEO retirement, a portfolio reshuffle, and ambitious regulatory timelines with multiple PDUFA dates extending into 2026 [10]. - Execution risk, margin compression, and leadership transitions are factors that may affect investor confidence, as highlighted by Nitorum's decision to divest [11].